Ingredient Science · Copper Tripeptide-1
GHK-Cu is the skin's endogenous repair signal. Levels fall 60% between age 20 and 60. Here is what the research actually says — and why concentration and delivery route determine whether it does anything at all.
GHK-Cu — glycine-histidine-lysine copper complex — is one of the most extensively researched peptides in skin science. Originally isolated in the 1970s by Loren Pickart while studying liver cell longevity, it was later identified as an endogenous signal peptide naturally present in human plasma, saliva, and urine. Crucially, its concentration in plasma drops from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60 — a 60% decline that correlates precisely with the age-related reduction in dermal collagen density and skin repair capacity.
GHK-Cu is having a renaissance in 2026 for two reasons. First, genomic research revealed that GHK — the peptide backbone, independent of the copper complex — modulates the expression of over 4,000 human genes, resetting aged fibroblast gene expression toward a younger, repair-competent phenotype. Second, the microneedling delivery model finally provides a mechanism to get GHK-Cu into the dermis at clinically relevant concentrations — something that intact-skin topical application has always struggled to achieve reliably.
The critical issue with most copper peptide products is not the ingredient — it is concentration. The studies showing measurable clinical outcomes used 1–3% GHK-Cu. The majority of products on the market contain 0.01–0.1%. Presence on an INCI list is not the same as a therapeutic dose.
GHK-Cu is the copper complex of the tripeptide glycine-histidine-lysine (INCI: Copper Tripeptide-1). It is an endogenous molecule — produced by the body, not foreign to it — and circulates naturally in plasma, saliva, and urine, where it functions as a repair signalling molecule, recruiting fibroblasts and immune cells to sites of tissue damage.
The molecule was first isolated in 1973 by Loren Pickart, who observed that young human plasma restored albumin synthesis in aging liver cells — and identified GHK as the active fraction responsible. Subsequent decades of research established its role in wound healing, tissue remodeling, and anti-inflammatory signalling.
Molecular weight: approximately 340 Da. This is significant. Most therapeutic peptides have molecular weights of 1,000–10,000 Da; GHK-Cu's 340 Da places it just below the 500 Da passive skin penetration threshold, meaning it can cross intact skin to some degree — unlike the vast majority of peptides marketed in skincare. This is why GHK-Cu has genuine intact-skin topical activity, not just microneedling-dependent activity (though post-needling delivery is substantially better).
The copper component is essential — not incidental. GHK alone has biological activity, but copper binding is required for lysyl oxidase activation, the enzyme responsible for cross-linking collagen and elastin fibrils. Decomplexed or incorrectly formulated products that lose the copper association lose a substantial part of the mechanism.
GHK-Cu operates across five distinct verified mechanisms — more than any other single cosmetic peptide. The multi-pathway action is what separates it from single-mechanism actives like most growth factors or signal peptides.
GHK-Cu is the clearest example in skincare of the gap between ingredient presence and ingredient dose. The molecule is well-studied, the mechanisms are established, and the clinical results at studied concentrations are reproducible. But the majority of consumer products contain GHK-Cu at concentrations 10 to 100 times below what studies used.
| Product / Study | GHK-Cu % | Context |
|---|---|---|
| Typical consumer copper peptide serum | 0.01–0.1% | Label presence; sub-threshold dose |
| NIOD CAIS3 (market concentration benchmark) | 1% | At clinical threshold; intact skin topical |
| The Ordinary Buffet + Copper Peptides 1% | 1% | At clinical threshold; intact skin topical |
| Pickart et al. (wrinkle study) | 2% | 55.8% wrinkle depth reduction in RCT |
| CUVA R1 | 2% | Post-microneedling; enhanced dermal delivery |
GHK-Cu also exhibits competition effects in skin: other copper-binding molecules — metalloproteins, albumin, and chelating agents — compete for available copper ions. At sub-threshold concentrations, the competing molecules likely out-compete GHK-Cu entirely, leaving very little free copper available for LOX activation. This is the physiological basis for the threshold effect: there is a minimum concentration below which GHK-Cu's copper-dependent mechanisms simply do not operate.
At concentrations below ~0.5%, GHK-Cu's copper-dependent mechanisms (LOX activation, collagen cross-linking) are likely inhibited by endogenous copper competitors. The clinical evidence for GHK-Cu efficacy was established at 1–2% — this is the minimum meaningful dose for structural skin effects.
At 340 Da, GHK-Cu sits just below the 500 Da passive penetration threshold, meaning it can cross intact skin — unlike PDRN, which cannot. But "can cross" and "reaches the dermis in therapeutic quantities" are different claims. Passive topical delivery of GHK-Cu to the dermis is real but limited, influenced by formulation, pH, concentration gradient, and the lipid architecture of the stratum corneum.
Post-microneedling, the picture changes substantially. The most directly relevant study (PMID 25690343, Kang Lab at NUS, Pharmaceutical Research 2015) measured GHK-Cu skin tissue levels in ex vivo human skin. Microneedle pre-treatment delivered 134 ± 12 nmol/mg GHK-Cu in skin tissue over 9 hours. Through intact skin under identical conditions, the result was near zero — below detection limits.
This quantifies what the theory predicts: post-microneedling GHK-Cu delivery is not incrementally better than intact-skin delivery, it is categorically different. The micro-channels created by needling (0.3–1.5mm depth, face) create aqueous pathways that allow the molecule to transit directly to the upper dermis, where fibroblasts express the receptors GHK-Cu activates.
The 134 nmol/mg tissue figure is comparable to the lower range of concentrations used in injectable mesotherapy formulations of GHK-Cu — which are themselves a well-established clinical modality. This is the basis for the claim that post-microneedling topical GHK-Cu at 2% approaches injectable bioavailability in the relevant tissue compartment.
134 ± 12 nmol GHK-Cu per mg skin tissue absorbed in 9 hours with microneedle pre-treatment. Near-zero penetration through intact skin in same conditions. Study: Li, Low, Chong et al., Kang Lab, National University of Singapore, Pharmaceutical Research 2015.
All references cite published peer-reviewed studies under specific experimental or clinical parameters. Results are not a guarantee of product outcomes. CUVA products are cosmetics regulated under EU Regulation EC 1223/2009.
The most extensively researched copper peptide in skin science. 50+ years of published evidence. 4,000+ gene targets identified. Pickart wrinkle RCT (2%) and Leyden RCT (topical facial cream) are the definitive human clinical references. LOX activation (collagen cross-linking) is the structural mechanism no other peptide in this category replicates. INCI: Copper Tripeptide-1.
Alanine-Histidine-Lysine copper complex — structurally related, different tissue affinity. AHK-Cu shows stronger activity in hair follicle models and is more commonly used in scalp products. Limited direct comparison data to GHK-Cu in facial skin. For post-microneedling skin recovery, GHK-Cu has the superior evidence base.
GHK without copper has measurable biological activity — gene modulation effects are partially retained — but loses the copper-dependent mechanisms entirely: no LOX activation, no collagen cross-linking. Products using Tripeptide-1 (GHK) rather than Copper Tripeptide-1 (GHK-Cu) are missing the structural ECM mechanism that produces the most clinically meaningful skin outcomes.
Drives structural ECM remodeling: collagen/elastin cross-linking via LOX, TGF-β signalling, anti-fibrotic inflammatory control, gene expression reset across 4,000+ targets. Primary outcome: dermal matrix integrity and long-term structural regeneration.
Drives cellular repair via A2A receptor: fibroblast proliferation, collagen I synthesis, NF-κB suppression, nucleoside salvage for DNA repair substrate. Primary outcome: acute repair signalling and anti-inflammatory control in the immediate post-procedure window.
These molecules operate on entirely different receptor systems. GHK-Cu acts on fibroblast intracellular pathways, TGF-β receptors, and copper enzyme systems. PDRN acts on the extracellular A2A purinergic receptor. There is no mechanistic competition — they are additive. The clinical rationale for combining them in a single post-microneedling ampoule is that the post-procedure tissue environment simultaneously benefits from both: the acute cellular repair and anti-inflammatory signalling from PDRN, and the structural collagen remodeling and ECM organisation from GHK-Cu.
See also: PDRN complete science guide →
CUVA R1 contains 2% GHK-Cu (20,000 ppm) combined with 1% PDRN in a sterile single-use ampoule — formulated for the 4-hour peak absorption window after microneedling. Concentration matches the Pickart 2% study standard. Nothing is present for label effect.
Trade enquiries: [email protected]